Solid Tumor

Metastatic Colorectal Cancer

dasatinib

bevacizumab

Oxaliplatin

Capecitabine

Rocky Mountain Cancer Center

Duke Univeristy Medical Center

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.

Herbert Hurwitz, MD

Associate Professor of Medicine

Bristol-Myers Squibb

PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4, 6 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo sigmoidoscopies on week 9 and restaging scans on week 11. If no PD, option to continue treatment every 3 weeks until intolerance or progression (evaluated radiographically every 12 weeks).

PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo prostatectomy on week 9.

Prostate Cancer

PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10^8 infectious units; PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10^9 infectious units.

PROSTVAC-V/F

Nivolumab is to be administered as a flat dose of 240 mg over approximately 60-minutes via IV infusion.

Nivolumab

National Institutes of Health Clinical Center

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Detection of clinically important inflammation defined as a grade 3 diarrhea or colitis requiring steroids or anti cytokine therapy or not resolving to grade 1 or less within 28 days.

Evaluate changes in T-cell infiltration in the tumor after neoadjuvant treatment with PROSTVAC and nivolumab, relative to changes seen in a phase 2 trial with PROSTVAC alone in the neoadjuvant setting NCT02153918 (For neoadjuvant cohort).

National Cancer Institute (NCI)

Breast Cancer

Postmenopausal

Dual x-ray absorptiometry (DXA)

Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays

Blood draw

Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months
Cognitive tests - baseline, 6 months, 12 months
Depression assessment - baseline, 6 months, 12 months
Dietary calcium intake questionnaire - baseline

Questionnaire

Washington University School of Medicine

Effect of Aromatase Inhibitors on Bones and Genes

Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms

Personalized diet added with quinoa and flaxseed

Personalized diet without dietary supplement

Metabolic Syndrome

Nutritional and Metabolic Diseases

Quinoa

Flaxseed

personalized diet added with quinoa and flaxseed

Quinoa and Flaxseed

Epidemiología y determinantes sociales asociados a la obesidad y la diabetes tipo 2 en México

NORMA Oficial Mexicana NOM-037-SSA2-2012, Para la prevención, tratamiento y control de las dislipidemias.

Diferencias entre la prevalencia de obesidad y exceso de peso estimadas con datos declarados o por medición directa en adultos de la Comunidad Valenciana

Consumer Acceptability of Muffins with Flaxseed (Linum usitatissimum)

Flavonoids and other phenolic compounds in Andean indigenous grains: Quinoa (Chenopodium quinoa), kañiwa (Chenopodium pallidicaule) and kiwicha (Amaranthus caudatus)

Nutraceuticals and Functional Foods in Health Promotion and Disease Risk Reduction

Inhibition of reverse transcriptases by flavonoids

Utilidad de la Prueba de Micronúcleos y Anormalidades Nucleares en Células Exfoliadas de Mucosa Oral en la Evaluación de Daño Genotóxico y Citotóxico

Procedimientos básicos de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral

Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados

Hospital Civil de Guadalajara "Fray Antonio Alcalde"

Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara

Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients

Evaluation of the Citotoxicity and Clicemic Control of Subject With Metabolic Syndrome Managed With Conventional Nutritional Tratment More Quinoa, Flaxseed or Borh Versus Conventional Nutrition

The number of micronuclei will be evaluated at baseline at 12 weeks and 24 weeks with Schmidt technique by Giemsa/wright and the entered values reflect the number of micronuclei at week 24

The fasting glucose levels will be evaluated at baseline, at 12 weeks and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at 24 weeks

Glycosylated hemoglobin will be evaluated at baseline, at 12 weeks and 24 weeks by high-pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at 24 weeks

The body weight will be measured at baseline, at 12 weeks and 24 weeks with a bioimpedance balance and the entered values reflect the body weight at 24 weeks

Body Mass Index will be calculated at baseline, 12 weeks and 24 weeks with the Quetelet index formula and the entered values reflect the body mass index at 24 weeks

Waist circumference will be evaluated at baseline and at 24 weeks with a flexible tape

Total cholesterol levels will be evaluated at baseline and 24 weeks by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at 24 weeks

Triglycerides levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at 24 weeks

c-HDL levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at 24 weeks

c-LDL levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at 24 weeks

Blood pressure will be measured at baseline and 24 weeks with a digital sphygmomanometer and the entered values reflect the blood pressure at 24 weeks

El uso de los datos es exclusivo de los investigadores involucrados en el estudio sin la devulgacion de los mismos a terceros externos al equipo de trabajo

mountain/anticancerigen

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Effect of Aromatase Inhibitors on Bones and Genes

Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients

Cea mai completă bază de date cu plante medicinale susținută de știință